Effect of 4-week treatment with placebo or NVP DPP728 at 100 mg t.i.d. or 150 mg b.i.d. in subjects with type 2 diabetes on body weight, fasting and prandial glucose, and insulin and lipid levelslegend
| . | . | Placebo (n = 32) . | NVP DPP728 . | . | |
|---|---|---|---|---|---|
| . | . | . | 100 mg t.i.d. (n = 30) . | 150 mg b.i.d. (n = 30) . | |
| Body weight (kg) | Baseline | 82.6 ± 2.4 | 79.9 ± 2.0 | 77.9 ± 2.0 | |
| Change | −0.2 ± 0.3 | 0.1 ± 0.3 | −0.1 ± 0.3 | ||
| 24-h plasma glucose (mmol/l) | Baseline | 9.2 ± 0.3 | 8.9 ± 0.3 | 8.8 ± 0.3 | |
| Change | −0.1 ± 0.1 | −1.1 ± 0.1* | −1.0 ± 0.1* | ||
| 24-h plasma insulin (pmol/l) | Baseline | 157 ± 12 | 157 ± 13 | 153 ± 15 | |
| Change | 16 ± 8 | −9 ± 8† | −9 ± 8† | ||
| FPG (mmol/l) | Baseline | 8.7 ± 0.2 | 8.5 ± 0.3 | 8.5 ± 0.3 | |
| Change | 0.1 ± 0.2 | −0.9 ± 0.2* | −0.6 ± 0.2‡ | ||
| Glucose excursion§ (mmol/l) | Baseline | 4.1 ± 0.3 | 3.9 ± 0.2 | 4.1 ± 0.3 | |
| Change | −0.1 ± 0.2 | −1.2 ± 0.2* | −1.3 ± 0.2* | ||
| Prandial glucose∥ (mmol/l per h) | Baseline | 6.0 ± 0.8 | 4.8 ± 0.7 | 5.5 ± 0.7 | |
| Change | −0.0 ± 0.6 | −2.8 ± 0.6* | −3.0 ± 0.6* | ||
| Fasting insulin (pmol/l) | Baseline | 79 ± 6 | 81 ± 8 | 78 ± 7 | |
| Change | 4 ± 5 | −1 ± 5 | 5 ± 0 | ||
| Insulin-to-glucose excursion rate¶ (pmol/mmol) | Baseline | 12.6 ± 0.9 | 16.2 ± 1.7 | 15.9 ± 2.8 | |
| Change | 1.7 ± 0.8 | 3.6 ± 2.0 | 7.4 ± 2.1† | ||
| Total cholesterol (mmol/l) | Baseline | 5.8 ± 1.0 | 5.7 ± 0.8 | 5.5 ± 0.9 | |
| Change | 0.1 ± 0.1 | −0.2 ± 0.17† | −0.2 ± 0.1† | ||
| HDL cholesterol (mmol/l) | Baseline | 1.3 ± 0.5 | 1.3 ± 0.3 | 1.3 ± 0.3 | |
| Change | 0.01 ± 0.03 | 0.03 ± 0.03 | 0.02 ± 0.03 | ||
| LDL cholesterol (mmol/l) | Baseline | 3.7 ± 0.9 | 3.6 ± 0.8 | 3.5 ± 0.8 | |
| Change | 0.02 ± 0.09 | −0.17 ± 0.08 | −0.18 ± 0.09 | ||
| VLDL cholesterol (mmol/l) | Baseline | 0.35 ± 0.15 | 0.32 ± 0.16 | 0.32 ± 0.14 | |
| Change | 0.03 ± 0.02 | −0.02 ± 0.02† | −0.01 ± 0.02 | ||
| Triglycerides (mmol/l) | Baseline | 1.7 ± 0.7 | 1.7 ± 1.1 | 1.6 ± 0.7 | |
| Change | 0.14 ± 0.09 | −0.14 ± 0.09† | −0.09 ± 0.09 | ||
| . | . | Placebo (n = 32) . | NVP DPP728 . | . | |
|---|---|---|---|---|---|
| . | . | . | 100 mg t.i.d. (n = 30) . | 150 mg b.i.d. (n = 30) . | |
| Body weight (kg) | Baseline | 82.6 ± 2.4 | 79.9 ± 2.0 | 77.9 ± 2.0 | |
| Change | −0.2 ± 0.3 | 0.1 ± 0.3 | −0.1 ± 0.3 | ||
| 24-h plasma glucose (mmol/l) | Baseline | 9.2 ± 0.3 | 8.9 ± 0.3 | 8.8 ± 0.3 | |
| Change | −0.1 ± 0.1 | −1.1 ± 0.1* | −1.0 ± 0.1* | ||
| 24-h plasma insulin (pmol/l) | Baseline | 157 ± 12 | 157 ± 13 | 153 ± 15 | |
| Change | 16 ± 8 | −9 ± 8† | −9 ± 8† | ||
| FPG (mmol/l) | Baseline | 8.7 ± 0.2 | 8.5 ± 0.3 | 8.5 ± 0.3 | |
| Change | 0.1 ± 0.2 | −0.9 ± 0.2* | −0.6 ± 0.2‡ | ||
| Glucose excursion§ (mmol/l) | Baseline | 4.1 ± 0.3 | 3.9 ± 0.2 | 4.1 ± 0.3 | |
| Change | −0.1 ± 0.2 | −1.2 ± 0.2* | −1.3 ± 0.2* | ||
| Prandial glucose∥ (mmol/l per h) | Baseline | 6.0 ± 0.8 | 4.8 ± 0.7 | 5.5 ± 0.7 | |
| Change | −0.0 ± 0.6 | −2.8 ± 0.6* | −3.0 ± 0.6* | ||
| Fasting insulin (pmol/l) | Baseline | 79 ± 6 | 81 ± 8 | 78 ± 7 | |
| Change | 4 ± 5 | −1 ± 5 | 5 ± 0 | ||
| Insulin-to-glucose excursion rate¶ (pmol/mmol) | Baseline | 12.6 ± 0.9 | 16.2 ± 1.7 | 15.9 ± 2.8 | |
| Change | 1.7 ± 0.8 | 3.6 ± 2.0 | 7.4 ± 2.1† | ||
| Total cholesterol (mmol/l) | Baseline | 5.8 ± 1.0 | 5.7 ± 0.8 | 5.5 ± 0.9 | |
| Change | 0.1 ± 0.1 | −0.2 ± 0.17† | −0.2 ± 0.1† | ||
| HDL cholesterol (mmol/l) | Baseline | 1.3 ± 0.5 | 1.3 ± 0.3 | 1.3 ± 0.3 | |
| Change | 0.01 ± 0.03 | 0.03 ± 0.03 | 0.02 ± 0.03 | ||
| LDL cholesterol (mmol/l) | Baseline | 3.7 ± 0.9 | 3.6 ± 0.8 | 3.5 ± 0.8 | |
| Change | 0.02 ± 0.09 | −0.17 ± 0.08 | −0.18 ± 0.09 | ||
| VLDL cholesterol (mmol/l) | Baseline | 0.35 ± 0.15 | 0.32 ± 0.16 | 0.32 ± 0.14 | |
| Change | 0.03 ± 0.02 | −0.02 ± 0.02† | −0.01 ± 0.02 | ||
| Triglycerides (mmol/l) | Baseline | 1.7 ± 0.7 | 1.7 ± 1.1 | 1.6 ± 0.7 | |
| Change | 0.14 ± 0.09 | −0.14 ± 0.09† | −0.09 ± 0.09 | ||
Data are means ± SEM.
P < 0.001;
P < 0.05 versus placebo;
P < 0.05;
glucose excursion = difference between maximum glucose in the 4-h postbreakfast period minus mean of prebreakfast glucose;
prandial glucose = area under the 4-h plasma glucose curve after breakfast;
peak Δ postprandial insulin divided by peak Δ postprandial glucose after breakfast.